RNA-tar­geted thera­peut­ics hold great prom­ise and evolve rap­idly towards clin­ical applic­a­tion. The recent suc­cess­ful devel­op­ment and use of RNA vac­cines has made pub­lic head­lines – and today it appears pos­sible to also use RNA molecules in therapy.
Except for the liver, the prin­cipal bot­tle­neck of all nuc­leic acid thera­peut­ics remains their insuf­fi­cient deliv­ery to tar­get organs. rnat­ics aims to cir­cum­vent this prob­lem by mak­ing use of the unique prop­er­ties of scav­enger cells, the mac­ro­phages. All human organs con­tain a pop­u­la­tion of tis­sue res­id­ent mac­ro­phages that self-renew and execute man­i­fold key roles in tis­sue homeo­stasis and also in organ dis­ease. These tis­sue mac­ro­phages are designed by nature for high capa­city uptake of spe­cific higher molecu­lar weight struc­tures, includ­ing also RNA molecules.

Our vis­ion

We want to employ the unique nat­ural pha­go­cytic prop­er­ties of tis­sue res­id­ent mac­ro­phages as an effect­ive means of deliv­ery to organs pre­vi­ously not access­ible to nuc­leic acid therapeutics.


rnat­ics devel­ops thera­peut­ics that tar­get dis­ease-caus­ing RNAs in tis­sue mac­ro­phages, which provide tre­mend­ous thera­peutic oppor­tun­it­ies for mul­tiple diseases.


Pro­pri­et­ary mac­ro­phage-tar­get­ing tech­no­lo­gies to deliver nuc­leic acid thera­peut­ics to tis­sue res­id­ent mac­ro­phages, where they are taken up and become active.


Joint Pro­ject